The contribution of glial cells to Huntington's disease pathogenesis
Open accessAbstract
Glial cells play critical roles in the normal development and function of neural circuits, but in many neurodegenerative diseases, they become dysregulated and may contribute to the development of brain pathology. In Huntington's disease (HD), glial cells both lose normal functions and gain neuropathic phenotypes. In addition, cell-autonomous dysfunction elicited by mutant huntingtin (mHTT) expression in specific glial cell types is sufficient to induce both pathology and Huntington's disease-related impairments in motor and cognitive performance, suggesting that these cells may drive the development of certain aspects of Huntington's disease pathogenesis. In support of this imaging studies in pre-symptomatic HD patients and work on mouse models have suggested that glial cell dysfunction occurs at a very early stage of the disease, prior to the onset of motor and cognitive deficits. Furthermore, selectively ablating mHTT from specific glial cells or correcting for HD-induced changes in their transcriptional profile rescues some HD-related phenotypes, demonstrating the potential of targeting these cells for therapeutic intervention. Here we review emerging research focused on understanding the involvement of different glial cell types in specific aspects of HD pathogenesis. This work is providing new insight into how HD impacts biological functions of glial cells in the healthy brain as well as how HD induced dysfunction in these cells might change the way they integrate into biological circuits.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In Huntington's disease models, oligodendrocytes exhibit maturation and functional impairments associated with changes in SGK1 expression, particularly in myelination and maintenance.
“In HD models, oligodendrocytes exhibit maturation and functional impairments (Wilton and Stevens, 2020), associated with changes in SGK1 expression, particularly in myelination and maintenance”
From Serum/glucocorticoid regulated kinase 1 (SGK1) in neurological disorders: pain or gain (2024) · cites this paper as Wilton and Stevens, 2020
In “Mouse models of HD reveal deficits in oligodendrocyte biology and myelination” (page not provided), the review reports impaired myelin structure, gene expression, and remyelination in HD mice. It says impaired oligodendrocyte differentiation *could* explain early myelination deficits, but does not establish a maturation impairment. The Wilton and Stevens citation is attached to the clause before SGK1 expression, so that later association is not assessed here. (LLM, conf=0.85)
Experimental — accuracy not yet measuredNeuroinflammation and microglial activation are consistent features across neurodegenerative diseases, including AD, PD, HD, FTD, and ALS.
“Indeed, neuroinflammation and microglial activation are consistent features across neurodegenerative diseases, including AD,126–128 PD,86,129 HD,130,131 FTD,91,132 and ALS.89,133–135”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [131]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 243 · Cited by 112
- Authors
- Wilton, D. K., & Stevens, B.
- Affiliations
- Boston Children's Hospital (US)
- Broad Institute (US)
- Corresponding author
- Stevens, Beth
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 143
- Pages
- 104963
- ISSN
- 0969-9961 (ISSN-L)
- PMC
- PMC7433320
- OpenAlex
- W3037983184
- Cited by
- 112
- References
- 243
- Citations by year
- 2026: 16 · 2025: 9 · 2024: 22 · 2023: 28 · 2022: 20 · 2021: 14 · 2020: 3
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neurobiology of Disease (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01NS084298, R01NS092578)
- Huntington's Disease Society of America
- CHDI Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- Huntington's disease, glial cells, mutant huntingtin, neurodegeneration, presymptomatic disease, therapeutic target, motor and cognitive deficits
- MeSH terms
- Animals, Brain, Humans, Huntington Disease, Neuroglia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review